Overview of Labocof

What is Labocof?

Labocof is a proprietary combination medicine formulated as an oral solution (syrup) designed for the symptomatic relief of common discomforts associated with acute viral upper respiratory tract infections, such as the common cold and flu. The preparation's identity is defined by its complex, multi-component structure, classifying it as a synthetic pharmaceutical entity.

Quick Facts	Description
Active Ingredients	Nine components, including Paracetamol and Guaifenesin
Form	Oral solution (Syrup)
Pharmacological Class	Combination Expectorant, Antihistamine, Analgesic, and Decongestant
Common Use	Integrated symptomatic relief for cold/flu
Origin	Synthetic

What Type of Medicine is Labocof?

Labocof is categorized as a comprehensive respiratory remedy that draws from several pharmacological classes simultaneously, reflecting its integrated therapeutic approach. Its primary actions encompass expectorant, mucolytic, antihistamine, analgesic, antipyretic, and nasal decongestant effects. This contrasts with monotherapy drugs that target only one symptom. The product is a poly-component formulation intended for oral intake, thereby providing simultaneous pharmacological action across multiple symptom pathways. Combination cold and flu treatments of this type are widely accepted as a standard method for managing the diverse symptoms of upper respiratory illness.

Core Composition of the Labocof Formulation

The medicine is defined by its unique blend of nine active ingredients, suspended in an aqueous vehicle (syrup base). Key components include the well-known expectorant Guaifenesin, which helps thin respiratory secretions, the mucolytic Bromhexine, the first-generation antihistamines Chlorpheniramine Maleate and Diphenhydramine, the analgesic and antipyretic agent Paracetamol (Acetaminophen), and the nasal decongestant Phenylephrine Hydrochloride. Multi-ingredient cold and cough preparations are a common approach to managing complex symptom patterns. The inclusion of Menthol is a differentiating feature, providing a distinct local soothing effect on the throat.

General Purpose: Integrated Symptomatic Relief

The general purpose of Labocof is to provide integrated symptomatic relief by concurrently addressing the main, disruptive signs of a cold or flu. By combining its actions, the preparation aims to facilitate respiratory tract clearance by thinning accumulated mucus and phlegm, reduce irritation and discharge stemming from allergic symptoms and congestion, and mitigate systemic discomforts such as fever, headache, and general body pain. This comprehensive effect minimizes overall discomfort and supports the patient's recovery process from acute upper respiratory infections.

Regulatory References

Common Cold - MedlinePlus

What side effects are possible with Labocof?

Possible Side Effects and Safety Information for Labocof

The safety profile for Labocof, a combination medication, is defined by the known risks associated with its active components, which include Paracetamol (Acetaminophen) and Chlorpheniramine Maleate.

Adverse Reactions

The most common side effects are often neurological and gastrointestinal in nature. These may include sleepiness or drowsiness, dizziness, nausea, vomiting, stomach pain, indigestion, headache, and allergic reactions (rash, itching). Due to the antihistamine component, impaired coordination and dry mouth are also commonly reported.

Regulatory warnings emphasize the risk of serious adverse reactions, particularly those related to the Paracetamol component. These serious risks include severe liver damage or acute liver failure, especially with high doses or concurrent alcohol use. Immediate medical attention is required for signs of severe allergic reactions (e.g., swelling of the face, throat, or tongue, or difficulty breathing) and severe skin reactions like Stevens-Johnson syndrome or Toxic Epidermal Necrolysis.

Specific Safety Considerations and Restrictions

Special caution is advised for several patient populations. The medication is generally considered unsafe for use during pregnancy and breast-feeding due to potential risks to the fetus or infant. Elderly patients should use it with caution, often requiring dose adjustments, due to increased susceptibility to side effects like confusion and sedation. Patients with pre-existing conditions such as moderate to severe kidney impairment, severe liver disease, narrow-angle glaucoma, or symptomatic prostatic hypertrophy have specific restrictions or are contraindicated from use.

Official documents strictly prohibit the use of alcohol due to the enhanced risk of central nervous system (CNS) depression and severe liver toxicity. Furthermore, due to the potential for drowsiness and impaired mental alertness, individuals are cautioned against operating machinery or driving after taking the medication.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents classify the overdose of Labocof as a life-threatening scenario primarily due to the risk of delayed, potentially fatal hepatic necrosis from the Acetaminophen component. Initial symptoms may be non-specific, involving nausea, vomiting, diaphoresis, and generalized malaise. Progressive toxicity can lead to severe abdominal pain and eventual jaundice.

The combination’s profile also mandates attention to Central Nervous System (CNS) and Cardiovascular effects. Overdose manifestations documented include profound drowsiness, seizures, or paradoxical excitation, alongside cardiac signs such as hypertension and arrhythmias.

Emergency Action and Required Management

Immediate medical attention must be sought at once following any known or suspected overdose, even if no symptoms are present. Regulators mandate that treatment to prevent severe liver damage must be initiated as quickly as possible. Official management includes symptomatic and supportive treatment, administration of N-acetylcysteine (NAC) as the specific antidote for Acetaminophen toxicity, and continuous hospital monitoring.

Serial liver function tests and cardiac monitoring are required to manage the documented systemic toxicological endpoints. Children and the elderly are noted to have increased susceptibility to the severe CNS effects of the antihistamine components.

The official structure mandates urgent supportive procedures and time-critical antidote administration to manage the documented, multi-component toxicological profile.

Therapeutic Uses of Labocof

What Labocof Treats: Main Uses and Benefits

Labocof is primarily used for providing integrated symptomatic relief across the diverse and complex symptom patterns associated with acute viral upper respiratory tract infections, such as the common cold and flu. The product is generally considered relevant for use across conditions characterized by periods of heightened symptoms where short-term symptomatic assistance is needed. Combination preparations are designed to address multiple symptoms simultaneously, including pain, fever, cough, and congestion.

This preparation is applied across domains where additional symptomatic support is needed for managing symptoms that interfere with daily functioning. This includes easing fever, generalized body pain and headache; managing nasal congestion and watery discharge; and addressing phlegm and mucus associated with a productive cough. The core intent is to offer symptomatic relief that helps patients cope more steadily with difficult episodes.

“The primary goal of this combination therapy is to support the patient during episodes of heightened discomfort by easing the overall symptom burden.”

Quick Fact	Relief for Symptom
Systemic Symptoms	Fever, Headache, Body Pain
Respiratory Symptoms	Congestion, Runny Nose, Phlegm

Easing Systemic Discomforts and Febrile Symptoms

This therapeutic domain covers symptoms related to systemic imbalance, specifically the general body distress that often interferes with rest. The preparation is commonly used to help with pronounced symptoms like fever, generalized body pain, and headache. This provides supportive relief that helps ease the overall symptom burden and may assist patients in coping more steadily with difficult acute episodes.

Managing Congestion, Discharge, and Airway Symptoms

Labocof is applied across domains where additional symptomatic support is needed for both upper and lower airway discomfort. It helps address symptom clusters that include nasal congestion, excessive watery discharge (runny nose), and the build-up of phlegm and mucus. It supports the relief of airway symptoms, which contributes to improved day-to-day comfort and assists with maintaining functional stability when symptoms are more noticeable.

Regulatory References

NIH MedlinePlus overview of Cold and Cough Medicines

Eligibility and Restrictions for Use

Who Can and Cannot Use Labocof?

The population eligibility for Labocof is strictly defined by regulatory documents, distinguishing between groups permitted to use the medicine and those for whom use is contraindicated or restricted. This section summarizes official, labeled requirements.

Contraindicated Populations (Must Not Use)

Labocof is contraindicated and must not be used by patients with a documented hypersensitivity to any active component, or those with severe uncontrolled hypertension or severe coronary artery disease. The medicine is also prohibited for patients with severe hepatic impairment (severe liver disease), narrow-angle glaucoma, or conditions leading to urinary retention. Use is strictly prohibited for any patient concurrently taking, or having recently taken (within 14 days), a Monoamine Oxidase Inhibitor (MAOI).

Age and Physiological Restrictions

Population Group	Official Eligibility Status
Children under 2 years	Contraindicated (Prohibited)
Children 2 to 12 years	Not Recommended (Restricted)
Adults and Adolescents (12+ years)	Eligible under standard conditions
Pregnancy and Lactation	Not Recommended (Safety not established)

Conditional Use and Comorbidities

Use of Labocof requires special caution and assessment in patients with controlled hypertension, diabetes mellitus, hyperthyroidism, and pre-existing lung conditions. Regulatory documents restrict use in patients with both moderate renal impairment and moderate hepatic impairment.

What should I know about interactions with other medicines?

Prohibited Combinations and Pharmacodynamic Effects

The regulatory labeling for Labocof's components establishes a mandatory restriction against co-administration with Monoamine Oxidase Inhibitors (MAOIs). This combination is formally prohibited due to the significant risk of hypertensive crisis, which stems from the Phenylephrine component, alongside the potential for intensified central nervous system (CNS) and anticholinergic effects caused by the first-generation antihistamines.

A documented additive pharmacodynamic effect occurs with alcohol and other CNS Depressants, including sedatives, hypnotics, and opioids, resulting in reinforced CNS depression. The official profile also notes that co-administration with other Anticholinergic drugs and Sympathomimetic agents may lead to additive anticholinergic and vasoconstrictor effects, respectively.

Exposure Modification and Timing Rules

The Paracetamol component is subject to label constraints regarding exposure modification. Concurrent use with Warfarin and other Coumarin derivatives may increase the anticoagulant effect and the risk of bleeding, especially when Paracetamol is used for prolonged periods. Furthermore, Cholestyramine significantly reduces Paracetamol absorption, mandating a strict timing separation of at least one hour between administrations. The Phenylephrine component carries a noted risk of hypertension when used with Beta-blockers. The Guaifenesin component may interfere with specific laboratory tests for VMA and 5-HIAA.

Mechanism of Action

Labocof, a combination pharmaceutical, modulates multiple physiological systems through distinct molecular mechanisms. The chlorpheniramine component functions as a first-generation histamine H1 receptor antagonist, selectively binding to the H1 receptors located on peripheral cells. This binding prevents the action of endogenous histamine, thereby inhibiting histamine-mediated downstream signaling cascades.

The phenylephrine component targets alpha1-adrenergic receptors, primarily located on vascular smooth muscle, acting as an agonist. This interaction triggers the activation of the Gq protein pathway, leading to increased intracellular calcium concentrations and subsequent vasoconstriction in the localized microvasculature.

Bromhexine and guaifenesin alter the properties of respiratory tract secretions. Bromhexine acts as a mucolytic, which modifies the structure of mucopolysaccharide fibers in mucus, decreasing its viscosity. Guaifenesin acts as an expectorant, increasing the volume of less viscous secretions by stimulating gastric vagal afferent nerve endings, which initiates a reflex efferent parasympathetic response on the bronchial glands.

Finally, the paracetamol component exerts its central action primarily through inhibition of central cyclooxygenase (COX) enzymes, particularly COX-2, leading to reduced synthesis of prostaglandin mediators in the central nervous system. This results in the modulation of the hypothalamic thermoregulatory center.

Dosage and Administration Information

How to Use Labocof: Administration Guidelines

The following instructions detail the administration of Labocof. The medicine must be used exactly as prescribed by a healthcare provider.

Administration and Dosage Rules

Administration Scope	Requirement
Route of Administration	Oral (by mouth)
Dosing Schedule	Take the dose and for the duration as advised by the doctor. The dosage must not be increased
Timing with Meals	May be taken with or without food, but it is recommended to take it at a fixed time
Preparation Requirements	For liquid formulations (syrup), the bottle must be shaken well before measuring the dose
Administration Method	Swallow tablets whole; do not chew, crush, or break them. Use a proper measuring cup or spoon for liquid formulations to ensure an accurate dose
Missed Dose	Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue the regular schedule. Do not take a double dose

Procedural Structure

Guidelines structure the use of Labocof by first requiring a physician-defined dosage and duration, which provides the treatment framework. Patients must follow the administration method, such as swallowing the tablet whole, or shaking the liquid and using a measuring device, which standardizes the physical intake of the medicine. Adherence to a fixed daily timing and a strict limit on the maximum dose (e.g., not exceeding a specified number of doses in 24 hours) is required to maintain the intended frequency and safety parameters of the drug.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Labocof

Evidence for Use in Overall Common Cold and Flu-like Syndrome

The primary research for multi-component oral solutions like Labocof has focused on short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These studies were used in research exploring how symptoms change over time by comparing the combination medicine against a placebo or individual active ingredients. Researchers applied these studies examining patient-reported experiences by measuring outcomes such as the Total Symptom Score (TSS) or a Global Effectiveness Rating to track the overall symptom burden in adults and older adolescents during the acute phase of illness.

What remains uncertain is the consistency of these patterns, as findings were mixed across specific trials and formulations. The follow-up durations were limited, usually lasting no more than 7 days, so long-term effects are not fully established. Evidence quality varies across studies, which contributes to the broader evidence landscape but does not offer certainty about the results.

Research on Systemic Discomforts (Fever, Pain, Headache)

Research examined the components of this combination that address systemic symptoms, such as fever, generalized body pain, and headache. This involved RCTs and systematic reviews focused on the known actions of the analgesic and antipyretic component (like Paracetamol). Studies monitored outcomes related to physical discomfort by tracking changes in specific symptom severity scores and temperature over defined, short time intervals, typically involving only a few doses.

Studies reported how symptoms evolved in the observed populations, documenting measurements showing a change in pain and temperature scores after administration of the active systemic component. However, the exact contribution of the component to the overall relief of symptoms specific to a cold or flu, when combined with nine other ingredients, was observed in some studies to be variable.

Studies Addressing Airway Symptoms (Congestion and Discharge)

The evidence base related to nasal congestion, runny nose, and sneezing was evaluated in studies exploring short-term symptom changes associated with the decongestant (Phenylephrine) and antihistamine (Chlorpheniramine/Diphenhydramine) components. Research examined outcomes linked to inflammatory or irritative states by measuring changes in Nasal Symptom Scores.

However, there is ongoing discussion and review by regulatory bodies regarding the specific research findings for the oral decongestant component (Phenylephrine), suggesting certainty remains low in this area. Furthermore, research highlights changes measured during the study period that were noted to be more pronounced for certain nasal symptoms (like runny nose) than for others (like congestion).

What is Still Uncertain About the Research Landscape

The evidence highlights what is known—and what is still uncertain—about these multi-component preparations. A key limitation is that evidence quality varies across studies, and findings were mixed regarding the consistency of reported effects across various similar multi-component formulations. The follow-up durations were limited, meaning that long-term effects are not fully established. Overall, while the research provides context for the study of acute, episodic symptom patterns, comparative evidence is lacking for this specific nine-component formulation against other types of combinations studied in trials.

Key Studies & References Summary of the evidence | Cough (acute): antimicrobial prescribing | Guidance - NICE

Frequently Asked Questions (FAQ)

Common questions about Labocof (FAQ)

Q: How quickly does Labocof start to work?

A: The official product information indicates that research on Labocof focuses on tracking short-term symptom changes after administration. However, a specific time-to-peak relief is not established for the medicine's combined effects. It is intended for the symptomatic relief of acute illnesses.

Q: Can Labocof be taken with common cold medicines?

A: Official guidance restricts the use of Labocof with other cold medicines. It is restricted from being used with other products containing Paracetamol (Acetaminophen) to avoid the risk of severe liver toxicity. Use is also restricted with other antihistamines or sympathomimetics (decongestants) to prevent excessive side effects.

Q: How long can I safely take Labocof?

A: The medication is intended for short-term use, and official guidance confirms it should be taken only for the duration specified by a healthcare provider. Clinical research studies tracking the effectiveness of the drug typically have a limited follow-up, usually lasting no more than seven days.

Q: How long does the effect of Labocof last?

A: The dosing schedule indicates the medicine is typically taken at fixed intervals to maintain its therapeutic effect. The precise therapeutic duration for a single dose is not detailed in the administration instructions.

Q: Can Labocof be taken if I have diabetes?

A: Official product information states that use may be considered in individuals with diabetes mellitus, but requires special caution. This is because one of the active ingredients, Phenylephrine, may potentially affect blood sugar control.

Q: Is Labocof safe for someone with kidney issues?

A: According to the official product information, there are restrictions for use in patients with moderate to severe kidney impairment (renal impairment). A healthcare provider needs to assess eligibility, as dose adjustments may be necessary due to its restrictions for use in this population.

Q: Can Labocof be crushed or mixed with food?

A: If using the tablet form, regulatory instructions specify that tablets must be swallowed whole and should not be chewed, crushed, or broken. If you are using the liquid (syrup) formulation, you must shake the bottle well before measuring the dose with a proper device.

Q: Does Labocof make you drowsy or sleepy?

A: Official warnings list sleepiness or drowsiness as a very common side effect of the medicine. This is primarily due to the antihistamine component it contains.

Q: Can you take Labocof on an empty stomach?

A: Regulatory administration guidelines confirm the medicine may be taken with or without food. However, it is officially recommended that it be taken at a fixed time each day.

Q: Is it normal to feel a little dizzy after taking Labocof?

A: Official safety information lists dizziness as one of the common side effects of the medication. This means that experiencing mild dizziness is a documented and expected possibility.

Q: Does Labocof interact with herbal supplements?

A: Regulatory documents do not specifically list interactions with most common herbal supplements. Because of the risk of interactions with the active components, it is important to consult with a healthcare professional about any supplements you are taking.

Q: What should I do if I miss a dose of Labocof?

A: Official guidance confirms that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose should be skipped. A double dose should never be taken.

Q: Is Labocof a controlled substance?

A: Labocof, in its current multi-component formulation, is generally not classified as a high-risk controlled substance under regulatory scheduling systems.

Q: Why is Labocof sometimes prescribed instead of other cough remedies?

A: Labocof is a multi-component preparation intended to provide integrated symptomatic relief. It is used to simultaneously address multiple symptoms of a cold or flu—such as fever, pain, congestion, and cough—which contrasts with monotherapy drugs that target only one symptom.

Q: Are there any warnings about driving while on Labocof?

A: Official warnings caution against operating machinery or driving due to the potential for drowsiness and impaired mental alertness associated with the medicine. This is a common warning for drugs containing sedating antihistamines.

Q: What are the inactive ingredients in Labocof?

A: Official labeling states that the active ingredients are suspended in an aqueous vehicle (syrup base) necessary to form the liquid solution. Inactive ingredients also include flavorings like Menthol, which provides a distinct local soothing effect.

Q: Has Labocof been extensively studied in clinical trials?

A: The medicine has been studied in short-term Randomized Controlled Trials (RCTs) to assess its effectiveness. However, regulatory text notes that evidence quality varies across studies and follow-up durations were limited, meaning that the long-term evidence base is not fully established.

Q: What is the typical duration of Labocof treatment?

A: The treatment is intended for acute, episodic symptom patterns associated with cold or flu. Clinical research follow-up durations were limited, often lasting no more than seven days, which provides context for the intended length of use.

Q: Does Labocof interact with SSRI antidepressants?

A: Specific interactions with the category of SSRI antidepressants are not detailed in the official list of drug interactions. However, it is important to consult a healthcare provider when considering combining Labocof with any CNS-acting medications due to the effects of the antihistamine and decongestant components.

Q: Does Labocof cause dry mouth?

A: Yes, dry mouth is listed in the official safety profile as a commonly reported side effect. This is a typical anticholinergic effect associated with the antihistamine component of the medicine.

Q: What kind of research supports the use of Labocof?

A: Support for the use of Labocof comes from short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies measure symptom changes by tracking outcomes like the Total Symptom Score and Nasal Symptom Scores when compared against a placebo or individual ingredients.

Q: Are there any long-term side effects associated with Labocof?

A: The regulatory documents state that long-term effects are not fully established. This is because the clinical trials conducted to support the drug's use had limited follow-up durations. The medicine is intended for short-term use.

How should Labocof be stored and disposed of?

How to Store and Dispose of Labocof?

Labocof oral solution must be stored according to the official instructions provided on its label to ensure its stability and potency. The regulatory requirements mandate storing the product at controlled room temperature, typically below 30 C (86 F). The solution must be kept in the original container, tightly closed, and protected from excessive heat, light, and moisture.

Storage Classification	Requirement
Temperature	Store below 30 C (86 F).
Container Rule	Keep in the original container, tightly closed.
Child Safety	Keep out of the sight and reach of children.

Disposal of unused or expired Labocof must adhere to official instructions. The preferred method is to utilize a drug take-back program or mail-back envelope. If such programs are unavailable, disposal should be done by mixing the solution with an undesirable substance (e.g., used coffee grounds) in a sealed container and throwing it into the household trash. The solution should not be flushed down a toilet or sink.

Labocof